Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

Related Articles by Review for PubMed (Select 19110201)

1.

Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?

Silver H, Chertkow Y, Weinreb O, Danovich L, Youdim M.

Neurotherapeutics. 2009 Jan;6(1):86-93. doi: 10.1016/j.nurt.2008.10.034. Review.

PMID:
19110201
2.

[Efficacy of atypical antipsychotics in depressive syndromes].

Quintin P, Thomas P.

Encephale. 2004 Nov-Dec;30(6):583-9. Review. French.

PMID:
15738862
3.
4.
5.

Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.

Chertkow Y, Weinreb O, Youdim MB, Silver H.

J Neural Transm. 2009 Nov;116(11):1529-41. doi: 10.1007/s00702-009-0255-4. Epub 2009 Jul 4. Review.

PMID:
19578925
6.
7.

Fluvoxamine as an adjunctive agent in schizophrenia.

Silver H.

CNS Drug Rev. 2001 Fall;7(3):283-304. Review.

PMID:
11607044
8.

[The place of SSRIs in the treatment of schizophrenia].

Zullino D, Delacrausaz P, Baumann P.

Encephale. 2002 Sep-Oct;28(5 Pt 1):433-8. Review. French.

PMID:
12386545
9.

[Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression].

Weimer E, Braus DF, Cavus I, Thome J.

Fortschr Neurol Psychiatr. 2002 Apr;70(4):210-7. Review. German.

PMID:
11948436
10.

The use of antidepressants in novel combination therapies.

Shelton RC.

J Clin Psychiatry. 2003;64 Suppl 2:14-8. Review.

PMID:
12625794
11.

Serotonergic approaches in the development of novel antipsychotics.

Jones CA, McCreary AC.

Neuropharmacology. 2008 Nov;55(6):1056-65. doi: 10.1016/j.neuropharm.2008.05.025. Epub 2008 Jun 3. Review.

PMID:
18621404
12.

Augmentation strategies for treatment-resistant depression.

Carvalho AF, Machado JR, Cavalcante JL.

Curr Opin Psychiatry. 2009 Jan;22(1):7-12. doi: 10.1097/YCO.0b013e32831be9ef. Review.

PMID:
19122528
13.

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Millan MJ.

Neurotherapeutics. 2009 Jan;6(1):53-77. doi: 10.1016/j.nurt.2008.10.039. Review.

PMID:
19110199
14.

Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2005 Jun;255(3):190-201. Review.

PMID:
15995903
15.

[The patient under antidepressive and antipsychotic therapy].

Hummel J, Lederbogen F.

MMW Fortschr Med. 2006 May 15;Spec no. 2:11-5; quiz 16. Review. German.

PMID:
20104708
16.

Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions.

Thomas KL, Ellingrod VL.

Pharmacotherapy. 2009 Jul;29(7):822-31. doi: 10.1592/phco.29.7.822. Review.

PMID:
19558256
17.

Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder.

Papakostas GI.

J Clin Psychiatry. 2009;70 Suppl 6:16-25. doi: 10.4088/JCP.8133su1c.03. Review.

PMID:
19922740
18.

Issues in polypharmacotherapy: focus on depression in schizophrenia.

Dufresne RL.

Psychopharmacol Bull. 1995;31(4):789-96. Review.

PMID:
8851655
19.

Novel antipsychotics in schizophrenia.

Mortimer AM.

Expert Opin Investig Drugs. 2004 Apr;13(4):315-29. Review.

PMID:
15102583
20.

[Pharmacogenetics and tailored drug treatment in schizophrenia].

Andreassen OA, Steen VM.

Tidsskr Nor Laegeforen. 2006 Sep 21;126(18):2400-2. Review. Norwegian.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk